These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 16986273)
21. Targeting: the ADEPT story so far. Bagshawe KD Curr Drug Targets; 2009 Feb; 10(2):152-7. PubMed ID: 19199911 [TBL] [Abstract][Full Text] [Related]
22. Strategies for enzyme/prodrug cancer therapy. Xu G; McLeod HL Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842 [TBL] [Abstract][Full Text] [Related]
23. Antibody-enzyme conjugates for cancer therapy. Melton RG; Sherwood RF J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489 [TBL] [Abstract][Full Text] [Related]
24. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Bagshawe KD; Sharma SK; Springer CJ; Rogers GT Ann Oncol; 1994 Dec; 5(10):879-91. PubMed ID: 7696159 [TBL] [Abstract][Full Text] [Related]
25. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Fang L; Sun D Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268 [TBL] [Abstract][Full Text] [Related]
26. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645 [TBL] [Abstract][Full Text] [Related]
27. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353 [TBL] [Abstract][Full Text] [Related]
28. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). Francis RJ; Mather SJ; Chester K; Sharma SK; Bhatia J; Pedley RB; Waibel R; Green AJ; Begent RH Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1090-6. PubMed ID: 15029458 [TBL] [Abstract][Full Text] [Related]
30. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666 [TBL] [Abstract][Full Text] [Related]
31. Theoretical analysis of conjugate localization in two-step cancer chemotherapy. Jackson TL; Lubkin SR; Murray JD J Math Biol; 1999 Oct; 39(4):353-76. PubMed ID: 10550578 [TBL] [Abstract][Full Text] [Related]
33. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Antoniw P; Springer CJ; Bagshawe KD; Searle F; Melton RG; Rogers GT; Burke PJ; Sherwood RF Br J Cancer; 1990 Dec; 62(6):909-14. PubMed ID: 2257218 [TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein. Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483 [TBL] [Abstract][Full Text] [Related]
35. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322 [TBL] [Abstract][Full Text] [Related]